| INTRODUCTION
Pulmonary arterial hypertension (PAH) is a complex disease of pulmonary vasculature characterized by an increase in pulmonary vascular resistance leading to right heart failure and eventually death.
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The histopathology of PAH is marked by sustained vasoconstriction, thickening of pulmonary artery walls, vascular remodeling. 4 The pulmonary vascular remodeling in PAH is characterized by pulmonary vascular medial hypertrophy and lumen narrowing, which is mainly caused by excessive proliferation and inadequate apoptosis in pulmonary artery smooth muscle cells (PASMCs). Chronic hypoxia is an important contributor to the development of clinical PAH, a fatal disease consisting of arterial constriction, vasculature remodeling, inflammation ensue and elevated thrombosis. However, the mechanisms of hypoxia-induced PASMCs proliferation remain largely unknown.
AKT, a serine/threonine protein kinase, is activated by a number of growth factors and cytokines in phosphatidylinositol-3 kinase (PI3K) dependent manner, and it may induce pro-proliferative and anti-apoptotic signaling pathways in a variety of cell types. 5, 6 Most of the malignant diseases are closely bound up with aberrant signaling of PI3K, including hypertension, atherosclerosis, cardiovascular disease and tumour. [7] [8] [9] In PAH, the PI3K/AKT pathway has been reported to be involved in PASMCs proliferation [10] [11] [12] and apoptosis. 13 The transient receptor potential vanilloid (TRPV) subfamily of TRP channels consists of six structurally similar but functionally unique proteins (TRPV1-V6), which the members of TRPV1-TRPV4
are all heat-activated non-selective cation channels. Transient receptor potential vanilloid 3 (TRPV3) is a Ca 2+ -permeable cation channel that is abundantly expressed in keratinocytes of the skin, as well as cells of the tongue, palate, testes, cornea, nasal epithelium, distal colon, and inner ear. 14, 15 TRPV3 is currently being investigated for its role in cutaneous physiology, specifically its role in thermal perception, inflammation, irritation and pain, wound healing, maintenance of skin barrier integrity, and hair growth. 16, 17 TRPV3 has been shown to promote the release of pro-inflammatory mediators and pruritigens, including ATP, nerve growth factor, chemokines and
ILs from cultured keratinocytes. [18] [19] [20] Moreover, several recent studies have demonstrated that arachidonic acid and other fatty acids, which are produced during inflammation, potentiate TRPV3 function. 21 In addition, the TRPV3-activator carvacrol has been reported to elevate cytosolic Ca 2+ concentration and promote proliferation in corneal epithelial cells. 22 Previous studies revealed that the proliferation rate in the oral epithelia of TRPV3 knockout mice was less than that of wild-type mice. 23 The TRPV3 agonists could prevent adipogenesis by inhibiting phosphorylation of insulin receptor substrate 1 (IRS-1), downstream PI3K/AKT, and the expression of adipogenic genes peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (C/EBPα). 24 However, the expression and underlying molecular mechanisms of TRPV3 in the PASMCs and pulmonary hypertension have not yet been examined. Therefore, in the current study, we aim at defining TRPV3 expression in lung tissues and whether TRPV3-coupled signaling is involved in the regulation of PASMCs proliferation and to analyse the role of TRPV3 on PI3K/Akt signaling in cultured PASMCs, which may help us better understand the pathophysiological role of TRPV3 in PAH.
| MATERIAL AND METHODS
For detailed Material and methods, please see Supporting Information.
| RESULTS

| Morphometric analysis of pulmonary vascular remodeling in human and rats and right ventricular hypertrophy in hypoxic rats
The morphology of pulmonary vessels was examined with TRPV3 staining and hematoxylin-eosin stain to show potential correlations of the morphological changes with remodeling. We found that the expression of TRPV3 in pulmonary vessels was upregulated in PAH humans than the vessels from normal humans ( Figure 1A ). In addition, the wall thickness of the pulmonary artery was shown by the hematoxylin and eosin stain (H&E). Medial thickening was found in medium-size PAs that were obtained from rats that were exposed to hypoxia for 9 days. There was a significant increase in the Wall Thickness/Vessel Radius ratio compared to that of normoxic rats ( Figure 1B,C) . More importantly, we observed chronic hypoxia-induced right ventricular hypertrophy, as shown in Figure 1D and E, the ratio of the heart weight/tibia length (HW/TL) and the weights of the right ventricle to the weights of left ventricle plus septum (RV/LV+S) were much higher in the rats that were exposed to chronic hypoxia than in those that were exposed to normoxia.
| The expression of TRPV3 and hypoxia-induced proliferation in vivo
We used western blot and immunohistochemistry stain to determine the expression of TRPV3 in rat lung tissues, the results showed that the expression of TRPV3 protein was increased in hypoxic rats compared to normoxic rats (Figure 2A ] i was recorded by laser scanning confocal microscope in different treatments. Values are denoted as mean ± SEM from at least three separate experiments. **P < .01 compared to Control; # P < .05 compared to Hypoxia; ## P < .01 compared to Hypoxia. "Con" means control, "Hyp" means hypoxia, "H'' means hypoxia, "R20" means Figure S1A ). These results suggest that TRPV3 may be involved in the process of proliferation and affected cell cycle of PAs in hypoxic rats.
| Effect of inhibitor Ruthenium Red on TRPV3-induced PASMCs proliferation and cell cycle progression under hypoxia
We have proved that TRPV3 plays an important role in hypoxiainduced PAH. We endeavored to confirm whether TRPV3 was involved in the proliferation of PASMCs. As shown in Figure 3A , the protein level of TRPV3 was increased after 6, 12, 24 hours exposed was significantly suppressed under hypoxia after treated with siTRPV3. The data are presented as the mean ± SEM. from at least three separate experiments. *P < .05 compared to Control; **P < .01 compared to Control; # P < .05 compared to Hypoxia; ## P < .01 compared to Hypoxia.
"Con" means control, "Hyp" means hypoxia, "H'' means hypoxia, "siNC'' indicates non-targeted siRNA, "siTRPV3" means siRNA targeted to TRPV3 Figure 4F ). In addition, our results showed that hypoxia significantly enhanced the tubulin polymerization compared with that in normoxia, however, after treating the cells with TRPV3 silencing, the microtubule formation was inhibited effectively ( Figure 4G ). Moreover, the increased protein expression of p-CaMKII on hypoxia was significantly suppressed by TRPV3 silencing ( Figure 4H ). And as shown in Figure 4I , from fluorescence intensity taken by laser scanning confocal microscope, specific siRNA was used to silence TRPV3 gene expression,
showing that the increased [Ca
2+
] i was significantly reduced under hypoxia. These results suggested that TRPV3 has a dominant effect on the cell cycle activity and promotes PASMCs growth and proliferation, eventually contributing to pulmonary vascular medial thickening.
| TRPV3 activated PI3K/AKT signal pathway in hypoxic PASMCs
Because PI3K/AKT signal pathway promoted cell survival and proliferation in PASMCs under hypoxia, 31 we further determined whether
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PI3K/AKT pathway is involved in TRPV3-induced PASMCs proliferation. As shown in Figure 5A , hypoxia not only significantly increased PI3K and AKT phosphorylation but also enhanced the total PI3K and AKT protein levels at 24 hours of hypoxia exposure compared to that of normoxia, and the effects were obviously reversed by the TRPV3 inhibitor. As Ruthenium Red is a chemical blockage of TRPV3, we used RNA interference technology to knock down the expression of TRPV3.
In Figure 5B , we can see the same conclusion that siTRPV3 inhibited the phosphorylated and total protein levels of PI3K and AKT pathway under hypoxia. The ratio of the phosphorylated PI3K and AKT to the total PI3K and AKT did not change, suggesting that the increase in PI3K
and AKT phosphorylation are due to the increase in protein expression.
| TRPV3 promoted PASMCs proliferation via PI3K/AKT pathway
To elucidate whether the PI3K/AKT pathway participates in TRPV3 Figure 6E ). As shown in Figure 6F and G, carvacrol significantly enhanced the PI3K and AKT protein levels under hypoxia compared with that in hypoxia alone, whereas the PI3K and AKT protein levels were suppressed after administration of LY294002 to the PASMCs. These results suggested that PI3K/AKT pathway may be involved in TRPV3-induced proliferation of PASMCs under hypoxia.
| DISCUSSION
In this study, the expression property and biological function of the TRPV3 protein were detected in PASMCs, and we demonstrated for the first time that the activation and expression of TRPV3 protein both promote proliferation of PASMCs and improve cell cycle progression under hypoxic condition, which is, at least in part, mediated via the PI3K/AKT pathway. These data support the hypothesis that TRPV3-PI3K/AKT axis plays an important role in pulmonary vascular remodeling in response to hypoxic stress.
Studies have indicated that some other TRP channels are expressed in lung tissues and PASMCs, and these channels were widely involved in pulmonary vasoconstriction, differentiation, migration, proliferation and pulmonary vascular remodeling, such as TRPC1, TRPC6, TRPM7, TRPV1, TRPV4. [32] [33] [34] [35] [36] Accumulating evidence suggests that carvacrol activated TRPV3-like cation currents in cerebral artery endothelial cells, 37 and the activation of TRPV3 channel could carvacrol under hypoxia in PASMCs, and the enhanced expression were suppressed after incubated with LY 294002. (E) Hypoxia promoted the cell number in the S plus G 2 /M phases compared with normoxia, which was augmented by carvacrol under hypoxia. However, the effect was reversed by using LY 294002 in PASMCs. (F, G) Hypoxia increased the expression of PI3K and AKT in PASMCs under hypoxia alone or in the presence of carvacrol, whereas LY 294002 decreased the effects. All of the values are denoted as means ± SEM. Data shown are representative of at least three independent experiments. **P < .01 compared to Control; # P < .05 compared to Hypoxia; ## P < .01 compared to Hypoxia; § P < .05 compared to H + Car. "Con" means control, "Hyp" means hypoxia, "H'' means hypoxia, "Car" means carvacrol, "C" means carvacrol, "LY'' means LY 294002 promoted the proliferation process of non-small cell lung cancer, 38 and the activation of TRPV3 decreased proliferation and preserved the pluripotency of Embryonic stem cells (ESCs). 39 However, the functional orientation, expression and the underling mechanisms that whether TRPV3 activation participates in hypoxia-mediated proliferation in PAH is still unclear. Consistent with this notion, in our experiment, we found that TRPV3 is overexpressed in the pulmonary vessels of human PAH lungs and hypoxic rats. uating the status of cell proliferation. 40 We found that the PCNA expression was up-regulated on hypoxic condition, but the effect was reduced in the presence of Ruthenium Red and siTRPV3. We further observed the TRPV3 on cell cycle progression.
The cell cycle plays a central role in cell proliferation, 41, 42 whereas how the cycle responds to the TRPV3 remains unclear.
The cell cycle is subdivided into four phases: DNA replication oc- and AKT under hypoxia compared to the hypoxia alone, while the effects were reduced after treated with LY294002 at PASMCs. As previously mentioned, the increase in PI3K and AKT phosphorylation are due to the increase in protein expression, one possible explanation for this phenomenon is that there may be some factors and transcription factors in the middle for bridge, which regulate the transcription and translation level of PI3K and AKT. Further investigation, which is also important in revealing the TRPV3 and PI3K/ AKT complexes interaction, should be addressed in future studies.
In conclusion, our results show that the expression of TRPV3 is apparently increased under hypoxia, TRPV3 inhibition and silencing decrease the effect of proliferation induced by hypoxia in PASMCs.
We elucidated a novel mechanism that the role of TRPV3 channel in hypoxic pulmonary vascular remodeling and its effect on cell viability, cell cycle progression in the process of PASMCs proliferation, which is, at least in part, mediated via the PI3K/AKT pathway. Furthermore, we can have hypothesis that upregulated TRPV3 channels in PASMCs may make patients more sensitive to carvacrol and some other aromatic compounds, and more likely to develop pulmonary vascular wall thickening, and ultimately, pulmonary hypertension. These results indicate that developing pharmacological interventions specially aimed at decreasing the gene expression of TRPV3 or inhibiting the function of TRPV3 may greatly help in the development of new therapeutic strategies for PAH.
